Bionor's mission is to enable the immune system to fight HIV infection. Bionor is the first company, which has successfully completed a clinical trial using the shock and kill approach, thereby creating a strong foundation for further advancing its therapeutic vaccine Vacc-4x and Vacc-C5 in combination with other agents towards a functional cure. The company believes it has first mover potential based on clinical results to date and early adoption of the shock and kill strategy. In December 2015, Bionor announced that the HIV trial REDUC with Vacc-4x and romidepsin successfully met its primary endpoint by reducing latent HIV reservoir and further demonstrated control of viral load. Bionor retains full ownership rights to the HIV immunotherapy Vacc-4x and Vacc-C5, i.e., the upside potential from partnering or licensing remains with the Company.
Company Details
- Employees
- 5
- Founded
- 1986
- Address
- Bryggegata 6, 5th Floor, Oslo,bionor Holding As 0250,norway
- Phone
- 47 23 01 09 60
- uh****@****rma.com
- Industry
- Biotechnology
- Website
- bionorpharma.com
- HQ
- Oslo, Bionor Holding AS
Bionor Holding As Questions
Bionor Holding As's helpline number is 47 23 01 09 60
Bionor Holding As's website is bionorpharma.com
Bionor Holding As's LinkedIn profile is https://no.linkedin.com/company/bionor-pharma-asa
Bionor Holding As has
5 employees.
View email and phone details for 5
employees at Bionor Holding As.
Bionor Holding As's industry is
Biotechnology
Bionor Holding As's top competitors are
Virometix Ag,
Hijos De Antonio Gaspar Rosa Sl,
Authera,
Nabas,
Calluna Pharma,
Innolipid,
Union Therapeutics A/s,
Astellas Pharma,
Regenics As,
Bavarian Nordic.
Bionor Holding As's support email address is uh@bionorpharma.com
Bionor Holding As's categories are Biotechnology
Bionor Holding As's founding year is 1986
